Roche Holding AG RHHBY
59.37 USD -0.08 (-0.13%)
At closeNov 6, 2026, 4:00 PM EST
58.22 Day range 59.61
41.22 52-week range 61.27
- YTD
- +15.13%
- 1 year
- +44.03%
- Market cap
- 378.43B
- EPS (ttm)
- 2.41
- P/E ratio
- 24.63
- YTD return
- +15.13%
- 1-year return
- +44.03%
- Volume
- 107.08K
- Avg volume
- 1.74M
- Open
- 58.32
- Previous close
- 59.45
- Day's range
- 58.22 – 59.61
- 52-week range
- 41.22 – 61.27
- Earnings date
- Feb 4, 2027
2Y +21.02 (+55.07%)
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.49 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 1.58 | 1.66 | +0.08 | +5.06% |
| Jan 29, 2026 | Dec 31, 2025 | 1.35 | 1.36 | +0.01 | +0.74% |
| Jul 24, 2025 | Jun 30, 2025 | 1.62 | 1.74 | +0.12 | +7.41% |
| Jan 30, 2025 | Dec 31, 2024 | 1.17 | 1.18 | +0.01 | +0.85% |
| Jul 22, 2024 | Jun 30, 2024 | 1.30 | 1.43 | +0.13 | +10.00% |
News
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs 
Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M 
Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts 
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy - Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine 
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease 
Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks 
Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis 
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Your note
Sign in to keep a note on RHHBY — it syncs with the Stock Master app.